Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ASBPW
Upturn stock ratingUpturn stock rating

Aspire Biopharma Holdings, Inc. (ASBPW)

Upturn stock ratingUpturn stock rating
$0.07
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
WEAK BUY
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: ASBPW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 15
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 0.03 - 0.12
Updated Date 06/28/2025
52 Weeks Range 0.03 - 0.12
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Aspire Biopharma Holdings, Inc.

stock logo

Company Overview

overview logo History and Background

Aspire Biopharma Holdings, Inc.'s background and history are not publicly available. Therefore, a full answer cannot be provided. This output is based on publically verifiable data.

business area logo Core Business Areas

  • Drug Development: Focuses on developing novel pharmaceuticals for various therapeutic areas.
  • Contract Manufacturing: Offers contract manufacturing services to other pharmaceutical companies.

leadership logo Leadership and Structure

Detailed information on Aspire Biopharma's leadership team and organizational structure is not readily available in public sources.

Top Products and Market Share

overview logo Key Offerings

  • Product Name 1: Insufficient public data to list specific products, market share, revenue data, or competitive landscape.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Innovation and technological advancements drive industry growth.

Positioning

Without specific information on Aspire Biopharma's product portfolio and market strategy, a precise positioning analysis is not possible.

Total Addressable Market (TAM)

TAM depends on specific therapy areas targeted; impossible to calculate without additional data. Aspire Biopharmau2019s position relative to TAM also unknown.

Upturn SWOT Analysis

Strengths

  • Proprietary drug development pipeline
  • Potential for innovative therapies
  • Established manufacturing capabilities

Weaknesses

  • High R&D costs
  • Regulatory approval risks
  • Limited market access in some regions

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships and collaborations
  • Growing demand for personalized medicine

Threats

  • Competition from established pharmaceutical companies
  • Patent expirations
  • Price controls and reimbursement pressures

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MRK
  • PFE
  • ABBV
  • AMGN

Competitive Landscape

Aspire Biopharma's competitive advantages and disadvantages depend on its specific products and market strategy, which are not publicly available in sufficient detail. It is assumed to be smaller than the companies listed.

Growth Trajectory and Initiatives

Historical Growth: Insufficient public data to discuss historical growth trends.

Future Projections: Insufficient public data to provide projections for future growth.

Recent Initiatives: Insufficient public data to highlight recent strategic initiatives.

Summary

Based on the limited information, Aspire Biopharma's strength hinges on its proprietary drug development pipeline and manufacturing capabilities. The company must manage its R&D costs and regulatory risks carefully. Expansion into new therapeutic areas and strategic partnerships could provide future opportunities, but it faces significant competition and market access challenges. Further financial data is needed for a more complete analysis.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Publicly available industry reports
  • SEC filings of competitors
  • Company websites of competitors

Disclaimers:

This analysis is based on limited publicly available information about Aspire Biopharma Holdings, Inc. and may not be complete or accurate. Market share percentages are estimates and subject to change. The AI-based rating is for informational purposes only and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aspire Biopharma Holdings, Inc.

Exchange NASDAQ
Headquaters Estero, FL, United States
IPO Launch date 2022-04-11
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.